Clinical trials: Neuroendocrine; Carcinoma
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
This phase Ib trial studies the best way of TLR8 Agonist VTX-2337 and cyclophosphamide in treating patients with a solid tumor that has spread from the primary site (place where it started) to other places in the body…
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma
- Trial name
- NCT02650635
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer, Melanoma
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs.
- Conditions
- Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT07160335
- Testing
- HLX17, US-sourced Keytruda®
- Where
- 69 sites in United States, China and 2 more
- Volunteers
- 174 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma
- Trial name
- NCT02893917
- Testing
- Cediranib, Olaparib
- Where
- 16 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Medullary Thyroid Cancer
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
In this registry it is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib).
- Trial name
- CaprelsaReg (NCT02109250)
- Testing
- Caprelsa
- Where
- 8 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- Genzyme, a Sanofi Company
Tumor, Cancer
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
Patients with metastatic cancer are generally treated with chemotherapy, which has improved median survival compared to best supportive care.
- Conditions
- Tumor, Cancer, Melanoma, Sarcoma
- Trial name
- NCT01215500
- Testing
- Hypofractionated RT
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Chicago
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
Differentiated Thyroid Carcinoma, Medullary Thyroid Carcinoma
Spanish Study for Molecular Characterization of Thyroid Carcinoma
This project is a retrospective observational study based on the molecular characterization of a Spanish population of patients with refractory radio-iodine differentiated thyroid cancer (DTC) and medullary thyroid carcinoma…
- Trial name
- MOLTHY (NCT04970134)
- Testing
- Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Oncomine Focus Assay Platform with 52 genes
- Where
- 12 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer.
- Conditions
- Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- NCT05312671
- Testing
- Atezolizumab, Carboplatin, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neuroendocrine Tumors, Neuroendocrine Carcinoma
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms
This study evaluates the possibility and the safety of performing local therapy for Pancreatic neuroendocrine neoplasms (PanNENs) using radiofrequency ablation of the tumor under ultrasonography (EUS) guidance.
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Carcinoma, Pancreas Neoplasm, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
- Trial name
- RAPNEN (NCT03834701)
- Testing
- EUS guided radiofrequency ablation
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Catholic University of the Sacred Heart
Solid Tumors
Study of SNH-118110 in Advanced Solid Tumors
This is a multicenter, open-label, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SNH-118110 administered orally.
- Trial name
- SNH-118110 (NCT07649200)
- Testing
- SNH-118110 Soft Capsules
- Where
- China
- Volunteers
- 240 people
- Sponsor
- ScinnoHub Pharmaceutical Co., Ltd.
Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer.
- Conditions
- Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma
- Trial name
- NCT06566092
- Testing
- LN-145/LN-144
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
This phase I trial studies the best dose of sonidegib when given together with pembrolizumab and to see how well they work in treating patients with solid tumor that has spread to other places in the body (advanced).
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04007744
- Testing
- Pembrolizumab, Sonidegib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
Pancreatic Cancer, Melanoma
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV)…
- Conditions
- Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
- Trial name
- NCT03098160
- Testing
- Evofosfamide, Ipilimumab
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Threshold Pharmaceuticals
Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Ivonescimab in the Treatment of Multiple Advanced Tumors
The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma.
- Conditions
- Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma
- Trial name
- NCT06683846
- Testing
- Ivocizumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
Neuroendocrine Tumors, Carcinoid Tumor
Personalized PRRT of Neuroendocrine Tumors
In this study, peptide receptor radionuclide therapy (PRRT) with 177Lu-Octreotate (LuTate) will be personalized, i.e. administered activity of LuTate will be tailored for each patient to maximize absorbed radiation dose to tumor…
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumor, Carcinoma, Neuroendocrine
- Trial name
- P-PRRT (NCT02754297)
- Testing
- 177Lu-Octreotate
- Where
- Canada
- Volunteers
- 275 people
- Sponsor
- CHU de Quebec-Universite Laval
Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
This phase II trial studies how well berzosertib (M6620) works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating patients with small cell lung cancer that has come back…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma
- Trial name
- NCT03896503
- Testing
- Berzosertib, Biopsy Procedure, Biospecimen Collection
- Where
- 33 sites in United States
- Volunteers
- 104 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors
Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer
This study is testing a new PET/CT scan that uses a special tracer called [⁶⁸Ga]Ga-DLL3 nanobody to see if it can better detect cancer spread (metastases) in people with neuroendocrine tumors than the standard scans currently…
- Trial name
- DSC-NEC (NCT07733024)
- Testing
- 68Ga-PFD3
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Tingting Yuan
Colorectal Medullary Carcinoma
Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study
Medullary carcinoma (MC) is a rare tumor with solid growth pattern without glandular differentiation and constitute less than 1% of colorectal cancer.
- Trial name
- NCT03774862
- Volunteers
- 13 people
- Sponsor
- V.K.V. American Hospital, Istanbul
Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
This is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received…
- Conditions
- Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas, Neuroendocrine Carcinoma of Prostate
- Trial name
- DeLLight (NCT06893783)
- Testing
- Tarlatamab
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Inkeun Park
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.